Swiss National Bank’s Trillium Therapeutics Inc. TRIL Stock Holding History

Swiss National Bank’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-172,190	Closed	-$3.01M	–	2782
2021 Q3	$3.01M	Buy	172,190 +4,400	+3%	+$51.4K	﹤0.01%	1782
2021 Q2	$1.63M	Sell	167,790 -28,800	-15%	-$271K	﹤0.01%	2236
2021 Q1	$2.1M	Buy	196,590 +3,000	+2%	+$37.1K	﹤0.01%	1970
2020 Q4	$2.85M	Buy	+193,590	New	+$2.79M	﹤0.01%	1704

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Swiss National Bank's TRIL Position: Q4 2021 in Review

Swiss National Bank sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 172,190 shares — an estimated $3.01M sold.

Swiss National Bank first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $3.01M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Swiss National Bank reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Swiss National Bank sold 172,190 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $3.01M.
Swiss National Bank first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
Swiss National Bank's Trillium Therapeutics Inc. position peaked at $3.01M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Swiss National Bank's 13F filing for Q4 2021, filed 8 Feb 2022.